AI-Powered Drug Repurposing for CNS & Psychiatric Conditions
Accelerating breakthrough treatments for underserved communities through computational discovery
NARep AI: Computational Drug Repurposing for Neurological & Psychiatric Conditions
We use artificial intelligence to identify new therapeutic uses for FDA-approved drugs, with a mission to address health disparities in Appalachian communities.
Three Pillars:
-
Academic and nonprofit researchers receive free computational drug repurposing analysis using NARep AI for CNS and psychiatric conditions. Submit your research question and receive comprehensive analysis within 3 business days, including mechanism details, dosing recommendations, and clinical evidence.
-
We conduct original research on conditions disproportionately affecting Appalachian communities:
Substance Use Disorders (opioid, alcohol, stimulant)
Treatment-Resistant Depression & PTSD
Chronic Pain & Central Sensitization Syndromes
Neurodevelopmental Disorders (30% higher prevalence in our region)
Our goal: rapidly translate discoveries into accessible treatments through provider education and implementation support.
-
Pharmaceutical companies and biotechs access NARep AI’s specialized CNS repurposing capabilities:
Indication expansion analysis
Custom AI platform development
Regulatory pathway optimization
Starting at $25,000 per analysis
See NARep AI in Action
Recent Analysis: Early Alzheimer's Disease
NARep AI identified 5 novel anti-inflammatory repurposing candidates from a single query:
-
"Identify repurposing candidates for early-stage Alzheimer's disease focused on neuroinflammation. Must have: CNS penetration data, anti-inflammatory mechanism, compatible with cholinesterase inhibitors, and measurable biomarkers for 6-month trials."
-
Sargramostim (Cancer treatment)
Novel intranasal delivery approach
Shifts microglia from inflammatory to reparative state
Montelukast (Asthma drug)
Strong preclinical
Novel CNS-optimized formulation to enhance penetration
Candesartan
Confirmed blood-brain barrier penetration and neuroprotective mechanisms through AT1 receptor blockade and AT2 receptor activation
Off-patent in January 2014
-
These FDA-approved drugs could potentially be tested for Alzheimer's in 2-3 years rather than the 10-15 years needed for new drug development.
The Appalachian Health Crisis
-
45% higher opioid overdose rate than national average
1 in 3 adults experience chronic pain
76% of counties have psychiatrist shortages
$2.3B annual economic burden from untreated mental health conditions
-
Traditional drug development is too slow and expensive for communities in crisis. By repurposing existing drugs through NARep AI:
Time to treatment: 2-3 years (vs 10-15)
Development cost: 90% reduction
Safety profile: Already established
Access: Uses medications already in pharmacies
-
Free analyses provided to 50+ research teams
3 candidates identified for opioid use disorder
Active collaborations with regional health systems
Open-access publication advancing the field